PlainPharmaWatch

CMS Open Payments · Program Year 2024

Calliditas Therapeutics US Inc.

Calliditas Therapeutics US Inc. reported $1,997,506.46 in payments to 12,051 physicians and teaching hospitals across 12,052 transactions.

See the rankings → How this is sourced
$2.0M
Total payments
12,052
Transactions
12,051
Recipients
+$717.6K
General Payments vs PY2023

Calliditas Therapeutics US Inc. reported $1,997,506.46 in payments to 12,051 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #448 of 1,925 reporting manufacturers (0.0% of all US industry payments), averaging $165.75 per recipient across 6 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

Calliditas Therapeutics US Inc. pairs top-quartile payment volume with an unusually diversified payment pattern across a wide recipient base.

#448
of 1,925 companies
0.0%
of all US industry payments
0.1%
paid to its single top recipient
6
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

Calliditas Therapeutics US Inc.'s CMS-reported General Payments increased by $717.6K (+56.5%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2022: CALLIDITAS THERAPEUTICS US INC.PY2023: CALLIDITAS THERAPEUTICS US INC.PY2024: CALLIDITAS THERAPEUTICS US INC.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$1.3MPY2024$2.0M
PY2023
$1,269,069.99
PY2024
$1,986,661.46

How Calliditas Therapeutics US Inc. ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

Calliditas Therapeutics US Inc.'s total vs. every reporting company

CMS Open Payments, Program Year 2024

$1,997,506 Top 23% higher than 77% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). Below this entry. $242,294–$752,621: 270 reporting companies (14%). Below this entry. $752,621–$2,337,813: 263 reporting companies (14%). This entry sits in this band. $2,337,813–$7,261,783: 200 reporting companies (10%). Above this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). Above this entry. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for Calliditas Therapeutics US Inc.

Rank #448 of 1,925 companies in CMS Open Payments for 2024 belongs to Calliditas Therapeutics US Inc., which reported $1,997,506.46 across 12,052 transactions to 12,051 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $165.74 per transaction and $165.75 per recipient.

The 6-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Honoraria" at $878.3K, accounting for 44.0% of the company's reported total and 389 transactions.

General Payment Breakdown by Type

Calliditas Therapeutics US Inc. made 6 types of general payments. "Honoraria" is the largest category at $878.3K, 44.0% of the company's reported total.

How Calliditas Therapeutics US Inc. divides its payments

General-payment categories, ordered by reported total

1. Honoraria$878.3K2. Consulting Fee$472.9K3. Food and Beverage$353.3K4. Travel and Lodging$280.4K5. Space Rental or Facility …$1.5K6. Education$250.00
Payment Type Amount Transactions
Honoraria $878.3K 389
Consulting Fee $472.9K 198
Food and Beverage $353.3K 10,966
Travel and Lodging $280.4K 492
Space Rental or Facility Fees $1.5K 1
Education $250.00 5

Recipient Concentration in General Payments

The five largest recipient relationships account for $441,104.43 (22.2%) of $1,986,661.46 in this company's General Payments records across 4,527 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Calliditas Therapeutics US Inc.

The five named recipients with the highest reported General Payments from this company

Gerald Bernard Appel$122.9KJorge Antonio Larranaga$106.3KSreedhar a Mandayam$74.3KAnis a Rauf$69.2KSayna Norouzi$68.4K
  1. 1

    Gerald Bernard Appel

    $122,899.83 across 94 reported transactions

  2. 2

    Jorge Antonio Larranaga

    $106,250.71 across 102 reported transactions

  3. 3

    Sreedhar a Mandayam

    $74,332.61 across 97 reported transactions

  4. 4

    Anis a Rauf

    $69,181.56 across 80 reported transactions

  5. 5

    Sayna Norouzi

    $68,439.72 across 58 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $165.74. Average per recipient: $165.75.

Total Amount

$1,997,506.46

Avg per Transaction

$165.74

Avg per Recipient

$165.75

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

Calliditas Therapeutics US Inc. Share

0.0%

#448 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to Calliditas Therapeutics US Inc.

Biohaven Pharmaceutical Holding Company Ltd.

$2.0M 0 recipients

Shape Memory Medical Inc.

$2.0M 246 recipients

Roche Diagnostics Corporation

$2.0M 900 recipients

Immunocore Limited

$2.0M 1,028 recipients

Omnia Medical, LLC

$2.0M 110 recipients

Ferring Pharmaceuticals Inc.

$2.0M 21,199 recipients

Frequently Asked Questions

How much did Calliditas Therapeutics US Inc. pay to physicians and hospitals in 2024? ▾
0.0% of all industry payments reported to CMS Open Payments for 2024 came from Calliditas Therapeutics US Inc., totaling $1,997,506.46 across 12,052 transactions to physicians and hospitals.
How many physicians received payments from Calliditas Therapeutics US Inc.? ▾
Averaging $165.75 per recipient, Calliditas Therapeutics US Inc.'s 2024 payments reached 12,051 physicians and teaching hospitals.
What types of payments did Calliditas Therapeutics US Inc. make? ▾
Calliditas Therapeutics US Inc. made 6 different types of general payments (consulting, meals, travel, and similar categories). The largest general-payment category was "Honoraria" at $878.3K, representing 44.0% of the company's reported total.
How does Calliditas Therapeutics US Inc. rank among pharmaceutical companies? ▾
By total payment amount, Calliditas Therapeutics US Inc. sits at #448 of 1,925 companies in the CMS Open Payments database for 2024.
What is the average payment size from Calliditas Therapeutics US Inc.? ▾
The average transaction from Calliditas Therapeutics US Inc. was $165.74 in 2024. The company made 12,052 total transactions to 12,051 recipients.
Where does the payment data for Calliditas Therapeutics US Inc. come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Calliditas Therapeutics US Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.